Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

40.76 +0.26 (+0.64%)
Streaming Delayed Price Updated: 11:20 AM EST, Nov 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
Roche's Arthritis Drug, Used As COVID-19 Treatment, Faces Supply Shortage
Roche Holdings AG's (OTCQX: RHHBF) drug Actemra, or tocilizumab, was granted FDA emergency use authorization for critically ill COVID-19 patients after... 
Via Benzinga
AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved PFS Over Roche's Kadcyla In Breast Cancer
AstraZeneca plc (NASDAQ: AZN) and Daiichi Sankyo Co Ltd (OTC: DSKYF) have announced high-level results from the head-to-head DESTINY-Breast03 Phase 3... 
Via Benzinga
Genentech's Polivy Plus R-CHP Shows Prolonged Survival In Newly Diagnosed DLBCL Patients
Genentech, a member of Roche Holdings AG (OTC: RHHBY), announced that the pivotal Phase 3 POLARIX trial met its primary endpoint in people with previously... 
Via Benzinga
Phase III Study Shows Genentech's Polivy Plus R-CHP Is the First Regimen in 20 Years to Significantly Improve Outcomes in Previously Untreated Aggressive Form of Lymphoma Compared to Standard of Care
From Genentech
Via Business Wire
These OTC Securities Had the Most Trading Activity in July
Photo by Federico Beccari on Unsplash In July, O... 
Via Benzinga
Moderna Vs. BioNTech: How Do These High-Flying COVID-19 Vaccine Stocks Compare?
Moderna, Inc. (NASDAQ: MRNA) and BioNTech SE (NASDAQ: BNTX) shares have been on tear ever since these companies embarked on their respective COVID-19 vaccine programs. Shares of... 
Via Benzinga
Billionaire Masayoshi Son's SoftBank Claims $5B Stake In Roche: Bloomberg
SoftBank Group Corp (OTC: SFTBF) has quietly acquired a $5 billion stake in Roche Holdings AG (OTC: RHHBF), making it one of the largest investors of the Roche,... 
Via Benzinga
Outlook Therapeutics Stock Surges Positive ONS-5010 Data In Wet AMD Patients
Outlook Therapeutics Inc (NASDAQ: OTLK) stock is trading higher in premarket session in reaction to positive top-line results from Phase 3 NORSE TWO trial... 
Via Benzinga
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Roche's Tecentriq As Adjuvant Treatment Under Priority Review With FDA For Early Lung Cancer
The FDA has granted priority review for Genentech's, a unit of Roche Holdings AG (OTC: RHHBY) Tecentriq (atezolizumab), as adjuvant treatment for... 
Via Benzinga
FDA Grants Priority Review to Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-small Cell Lung Cancer
From Genentech
Via Business Wire
Know When To Hold 'Em, Know When To Fold 'Em ...
A long Monday list identifying some sensible and some impenetrable moves behind today's market in our stocks. 
Via Talk Markets
FDA Approves Regeneron - Roche's COVID-19 Antibody Cocktail For Post-Exposure Prophylaxis
Following the June update that 
Via Benzinga
How AbbVie Could Make an Entry Into This Rapidly Growing Drug Market
Venclexta's potential indication for the treatment of myelodysplastic syndrome could mean billions for AbbVie this decade. 
Via The Motley Fool
Roche's Faricimab US Application For Ocular Diseases Under Priority Review
The FDA has accepted Roche Holding AG's (OTC: RHHBY) Biologics License Application seeking approval for faricimab in neovascular of wet age-related macular... 
Via Benzinga
FDA Accepts Application for Genentech’s Faricimab for the Treatment of Wet Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)
From Genentech
Via Business Wire
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Data for Genentech’s Evrysdi (risdiplam) Published in New England Journal of Medicine Shows Significant Improvement in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
OTC Markets Hits Major Milestones in Mid-Year Along With Big Volume and Gaining Securities
Photo by Kyrie Kim on Unsplash In a similar vein to 2020, the market’s volatility to start 2021 gave way to less volatility in the second quarter, and even less volatility... 
Via Benzinga
Infinity Pharma Stock Drops After Updated Data From Bladder & Breast Cancer Trials, Q2 Earnings
Infinity Pharmaceuticals Inc (NASDAQ: INFI) has issued data updates from two mid-stage trials for eganelisib, its oral immuno-oncology candidate. Data: 49... 
Via Benzinga
Joblessness Surprise
Despite higher production for the Emirates the price of oil rose sharply today. More output should cut prices. 
Via Talk Markets
Roche Puts Alzheimer's Candidate, Gantenerumab In Spotlight; In Dialogue with FDA: Reuters
Roche Holding AG (OTC: RHHBY) is reportedly talking to the FDA about its Alzheimer’s disease drug candidate, gantenerumab. CEO Severin Schwan declined... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 22, 2021
Upgrades According to Stephens & Co., the prior rating for World Acceptance Corp (NASDAQ:... 
Via Benzinga
Rebound In COVID-19 Tests Lift Roche's Half-Year Sales, Oncology Still Hit By Biosimilars, Pandemic
Roche Holding AG's (OTC: RHHBY) 1H 2021 sales increased by 8% Y/Y at constant exchange rates (CER) to CHF 30.7 billion as peak demand for COVID-19 tests helped... 
Via Benzinga
Panic Attack
The H1 rise in US markets was based on hope for an end to lockdowns. 
Via Talk Markets
Spark Therapeutics' Hemophilia Gene Therapy Achieve Stable, Durable FVIII Expression
Spark Therapeutics, a unit of Roche Holdings AG (OTC: RHHBY), has announced updated data from the ongoing Phase 1/2 trial of SPK-8011 gene therapy in... 
Via Benzinga
AbbVie - Roche's Venclexta Receives Breakthrough Therapy Tag In High-Risk Myelodysplastic Syndromes
The FDA has granted Breakthrough Therapy Designation (BTD) to Venclexta (venetoclax) combined with azacitidine for the potential treatment of adult patients with... 
Via Benzinga
FDA Grants Breakthrough Therapy Designation for Venclexta in Combination With Azacitidine for the Treatment of Patients With Myelodysplastic Syndromes
From Genentech
Via Business Wire
The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Alnylam Pharmaceuticals,... 
Via Benzinga
Roche Unveils New Hemlibra Data Reinforcing Safety Profile In Hemophilia A
According to Roche Holding AG's (OTC: RHHBY) Genentech division, new data from a phase 3b study reinforces the safety profile of blockbuster hemophilia A... 
Via Benzinga
< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.